Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership
Eli Lilly has penned a research collaboration deal with Massachusetts-based biotech, Ascidian Therapeutics, to discover and develop drugs for kidney…
04 Jun 2026
Cellares and TScan to assess automated manufacturing of TSC-101 therapy
Cellares and TScan Therapeutics have entered an agreement to examine the use of automated manufacturing for TScan’s TSC-101 therapy in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS).…
04 Jun 2026
Regeneron and CytomX extend cancer therapy partnership to $4bn deal
Regeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership to develop conditionally activated bispecific antibody cancer therapies, with the deal’s total potential value rising to up to $4bn.…
03 Jun 2026
US lawmakers reveal policy to curb collaboration with Chinese biotech
Two bipartisan Michigan lawmakers have joined forces to debut new legislation that, if enacted, could significantly suppress dealmaking between Chinese and American biotech and pharma companies. Together, Republican John Moolenaar…
03 Jun 2026
Contraline secures $92.5m to push male contraceptive into late-stage trials
Contraline has closed a $92.5m Series B financing round to take its topical male contraceptive to late-stage trials – potentially positioning the company with a first-to-market advantage in the male…
03 Jun 2026
AbbVie receives EC approval for Aquipta to treat migraine
AbbVie has received approval from the European Commission (EC) for Aquipta (atogepant), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine in adults, with or…
03 Jun 2026
Roche’s giredestrant secures FDA priority review for breast cancer
The US Food and Drug Administration (FDA) has accepted priority review of the new drug application (NDA) for Roche’s investigational oral selective oestrogen receptor degrader (SERD), giredestrant, for breast cancer.…